Philogen S.p.a.

Schwager, Kathrin

Kathrin Schwager

Manuela Kaspar

Eveline Trachsel

Giovanni Neri

Jianqing Chen

Melanie C Ruzek

Denise M O'Hara

Melanie Ruzek

Denise M O'hara

Denise O'hara

Denise O'HARA

The invention relates to a binding member that binds the Extra Domain-A (ED-A) isoform of fibronectin for the detection and treatment of rheumatoid arthritis.

Antigen associated with rheumatoid arthritis

Specific binding members that bind the ED-A isoform of fibronectin for use in methods of treatment, diagnosis, detection and/or imaging of inflammatory bowel disease (IBD), and/or for use in delivery to the IBD tissue of a molecule conjugated to the specific binding member. The specific binding member may, for example, be conjugated to an immunosupressive or anti-inflammatory molecule, such as interleukin-10.

Anti-ED-A immunoconjugates for inflammatory bowel disease

Methods and compositions for treating tumors, especially skin tumors, by locally administering single doses of tumor necrosis factor alpha (TNF&#x3b1;) and interleukin-2 (IL2) at the tumor site, where the TNF&#x3b1; and IL2 are delivered as immunoconjugates comprising an antibody targeted to a splice isoform of an extracellular matrix component such as fibronectin.

Immunocytokine combination therapy

Specific binding members that bind the ED-A isoform of fibronectin for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, and/or for use in delivery to the neovasculature of endometriotic tissue of a molecule conjugated to the specific binding member. Specific binding members that bind tenascin-C, especially the A1, A2, A3, A4 and/or D domain tenascin-C large isoform, for use in methods of diagnosis, detection, imaging and/or treatment of endometriosis, psoriatic arthritis or psoriasis, and/or for use in delivery to the neovasculature of endometriotic, psoriatic arthritic or psoriatic tissue of a molecule conjugated to the specific binding member.

Antigens associated with endometriosis, psoriatic arthritis and psoriasis

The invention provides a blocking ligand specific for CTLA-4 and a vascular targeting ligand/IL-2 complex, for sequential use in inhibiting the growth of tumor cell.

Growing community of inventors

Zurich, Switzerland

Kathrin Schwager